GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genovate Biotechnology Co Ltd (ROCO:4130) » Definitions » Additional Paid-In Capital

Genovate Biotechnology Co (ROCO:4130) Additional Paid-In Capital : NT$210.7 Mil(As of Mar. 2025)


View and export this data going back to 2012. Start your Free Trial

What is Genovate Biotechnology Co Additional Paid-In Capital?


Genovate Biotechnology Co's quarterly additional paid-in capital stayed the same from Sep. 2024 (NT$210.7 Mil) to Dec. 2024 (NT$210.7 Mil) and stayed the same from Dec. 2024 (NT$210.7 Mil) to Mar. 2025 (NT$210.7 Mil).

Genovate Biotechnology Co's annual additional paid-in capital increased from Dec. 2022 (NT$210.5 Mil) to Dec. 2023 (NT$210.6 Mil) and increased from Dec. 2023 (NT$210.6 Mil) to Dec. 2024 (NT$210.7 Mil).

Genovate Biotechnology Co Additional Paid-In Capital Historical Data

The historical data trend for Genovate Biotechnology Co's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genovate Biotechnology Co Additional Paid-In Capital Chart

Genovate Biotechnology Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 208.75 208.93 210.51 210.56 210.66

Genovate Biotechnology Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 210.66 210.66 210.66 210.66 210.66

Genovate Biotechnology Co Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Genovate Biotechnology Co Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Genovate Biotechnology Co's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Genovate Biotechnology Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genovate Biotechnology Co Ltd (ROCO:4130) » Definitions » Additional Paid-In Capital
Comparable Companies
ROCO:6704 ROCO:6892 ROCO:7754 ROCO:6748 TPE:1762 ROCO:6461 ROCO:6676 ROCO:1295 ROCO:6580 ROCO:6846 VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
No.1, First Industrial Road, Hsin-Chu Expanded Park, Hukou Township, Guangdong Province, Hsin-Chu county, Hsin-Chu, TWN, 303036
Website
http://www.genovate-bio.com
Genovate Biotechnology Co Ltd develops, produces, manufactures, and sales of medicines for the prevention and treatment of diseases caused by viruses and bacteria, and medicines for the treatment of cardiovascular, gastrointestinal, cancer, and autoimmune diseases, etc. The company is also engaged in the sales of medicines for the prevention and treatment of diseases caused by viruses and bacteria, and medicines for the treatment of cardiovascular, gastrointestinal, cancer, and autoimmune diseases etc.

Genovate Biotechnology Co Headlines

No Headlines